SCHEMBL20114219

SCHEMBL20114219

CC(C(=O)Nc1ccc(C(F)(F)F)cc1)n1nc(-c2ccc(C#N)cc2)ccc1=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.56
MAPT P10636 6/20 0.49
POLB P06746 5/20 0.46
LMNA P02545 3/20 0.46
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
THRB P10828 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KIF11 P52732 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
F11 P03951 2/20 0.38
KLKB1 P03952 1/20 0.38
EPHX2 P34913 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CSGALNACT1 Q8TDX6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20113811 0.92 TP53 (0.64) TP53MAPTPOLBLMNATHRB
SCHEMBL20113816 0.89 MAPT (0.57) TP53MAPTPOLBLMNAPSEN1
SCHEMBL20114216 0.87 TP53 (0.59) TP53MAPTPOLBLMNATHRB
SCHEMBL20113814 0.87 TP53 (0.73) TP53MAPTPOLBLMNATHRB
SCHEMBL20113817 0.83 TP53 (0.52) TP53MAPTPOLBLMNATHRB
SCHEMBL20113815 0.82 TP53 (0.60) TP53MAPTPOLBLMNATHRB
SCHEMBL20120057 0.81 TP53 (0.54) TP53MAPTPOLBLMNATHRB
SCHEMBL20120054 0.81 TP53 (0.52) TP53MAPTPOLBLMNAPSEN1
SCHEMBL20113812 0.80 TP53 (0.57) TP53MAPTPOLBLMNATHRB
SCHEMBL21259980 0.79 MAPT (0.51) TP53MAPTPOLBLMNAPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. 2019-08-22 US disclosed
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. 2019-08-22 US disclosed
WO-2018081377-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS CFTR, PKD2, CLCN2 TP53 2421/4885MAPT 4874/4885POLB 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.